Ventoux Biosciences

Ventoux Biosciences, Inc. is a pre-clinical stage biotechnology company developing first-in-class, disease-modifying therapies for immune-fibrotic conditions. Our mission, driven by a patient founder, is to address underserved chronic conditions, beginning with Dupuytren's disease (palmar fibromatosis). Our lead small molecule asset, VEN-201, emerged from a data-driven discovery platform and is advancing as a potential non-surgical, pharmacologic solution. We are expanding VEN-201's therapeutic potential to include other high-need fibrotic conditions, such as Spinal Cord Injury (SCI). Leveraging a robust IP strategy, which includes our first issued U.S. Patent providing protection through 2044, and a team of seasoned experts, we are accelerating the delivery of novel treatments to halt disease progression.